Clinical trial · Interventional
Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients
NCT01408212CI-TRIAL-00019019terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): low recruiting
Summary
Brief summary (as posted)
This study aims for evaluating the effectiveness, safety and feasibility of additional acupuncture therapy for lung cancer patients who are under chemotherapy in an inpatient setting. The acupuncture therapy will be administered during a resting period between cycles of chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Acupuncture therapy
- interventionNames
- Procedure: Acupuncture treatment
Primary outcomes (1)
- measure
- Change score of Functional Assessment of Cancer Therapy-Lung (FACT-L) scale from baseline
- timeFrame
- 7-10 days during a rest period between chemotherapy cycles
Secondary outcomes (4)
- measure
- Change score of Functional Assessment of Cancer Therapy-Lung (FACT-L) scale from baseline
- timeFrame
- 4-5 weeks from baseline (3-4 weeks after treatment termination)
- measure
- Change score of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT fatigue) Scale from baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years of age * Karnofsky Performance Status (KPS) 60% or more * Undergoing antineoplastic chemotherapy for lung cancer * Able to provide informed consent Exclusion Criteria: * Brain metastasis, stroke or major psychiatric diseases * Active infection * Severe heart disease * Serious systemic diseases such as uncontrolled hypertension and diabetes mellitus * Acupuncture therapy within the previous three months * Communication disorder * Unwillingness to participate in the trial * Severe immunocompromised state (absolute neutrophils count \< 1000/cubic mm)
References
Publications (0)
Data not yet available
No reference posted for this study.